Asthma vs. COPD Discrimination
Asthma, COPD
Clinical DevelopmentActive
Key Facts
About The eNose Company
The eNose Company is pioneering breath analysis for medical diagnostics using its proprietary electronic nose technology. It has advanced its lead program for detecting lung cancer and COVID-19 into clinical validation and commercialization phases, with a broader pipeline targeting asthma, COPD, and other conditions. As a publicly traded company on Euronext Access Paris, it operates in a high-growth digital diagnostics market but faces risks related to clinical validation, reimbursement, and competition from established diagnostic methods and emerging AI-driven platforms.
View full company profileTherapeutic Areas
Other Asthma, COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM9378 (SKB378/WIN378) | Harbour BioMed | Phase 1 |
| HP-Betadex DPI Formulations | Aquilon Pharmaceuticals | Clinical |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | ANDA Filed/Approved |
| Respiratory Inhalation Portfolio (Generic) | Cipla | ANDA Filed/Approved |
| Wixela Inhub (Fluticasone/Salmeterol) | Viatris | Launched |
| RELVAR/BREO ELLIPTA | Innoviva | Commercial |